For the management of patients with advanced breast cancer or lymph node involvement, anthracycline-based chemotherapy, RT with regional nodal irradiation (RNI), and anti-human epidermal growth factor receptor 2 (HER-2) target therapy are commonly used for disease control. This evidence concerns the gene ERBB2 and breast cancer.